Psyched Wellness Commences Antioxidant and Anti-Inflammatory Study on Muscimol

Toronto, Ontario, January 06, 2020 – Psyched Wellness Ltd. (formerly Duncan Park Holdings Corporation) (CSE:PSYC, OTCQB:DCNPF, FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share that it has commenced a study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes via a nerve derived immunity and neuroprotective modulation models.

The study will be led by Brian Tancowny and will focus on determining the effectiveness of the active compound muscimol from the Amanita Muscaria mushroom for its potential dual antioxidant and anti-inflammatory properties. This preliminary work will focus on determining the potential role in health promotion via modulation of oxidative stress and inflammation. The mushroom, Amanita Muscaria naturally contains high levels of the active compound muscimol. This study will look at the potential neuroprotective effects of muscimol via neurotoxicity and immunomodulatory invitro cell - based models.

Antioxidants have been shown to reduce the risk of many diseases (including heart disease and certain cancers). Antioxidants can scavenge free radicals from the body cells and prevent or reduce the impact of the damage caused by oxidation. The protective effect of antioxidants continues to be studied around the world. Anti-inflammatory refers to the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs make up about half of analgesics, remedying pain by reducing inflammation as opposed to opioids, which affect the central nervous system to block pain signaling to the brain. Opioids have led to increased substance abuse by over prescribing and addictions. Muscimol if shown to have anti inflammatory properties may lead to a more effective natural therapeutic for treating many conditions.

“This initial preliminary study will provide more insight into the potential health and wellness properties of the active compound muscimol of the Amanita Muscaria mushroom, which may lead into advanced preclinical areas of study for further work into a natural therapeutic agent,” says Brian Tancowny.

Jeff Stevens, CEO of the Company says, “We are excited to explore the many potential uses of Muscimol, the active compound in Amanita Muscaria mushrooms. Our team continues to research new opportunities of this compound, and we look forward to providing insights into the new areas of focus soon.”